Personalized diagnostics remains one of the most significant barriers to personalized medicine. Dr. John Bartlett and his Diagnostic Development group are building a focused research program to support novel approaches to personalized medicine in breast, prostate and other cancer types. In collaboration with partners across Ontario and around the world, Dr. Bartlett is working to create and establish integrated omics approaches to cancer diagnosis.
Dr. Bartlett works with guideline panels (e.g., ASCO-CAP, TILs in breast cancer) to create better approaches to delivering novel assays in the clinic, bridging the gap between omics discoveries and cancer patients. These approaches are increasingly enabling more personalized treatment for cancer patients across Ontario and beyond.
Dr. Bartlett’s work is supported by several global partnerships including the EBCTCG and other clinical trial partners.
- Reader, University Department of Surgery, Level II Queen Elizabeth Building, Glasgow Royal Infirmary, University of Glasgow
- Reader in Molecular Pathology, School of Molecular and Clinical Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh
- Professor of Molecular Pathology, School of Molecular and Clinical Medicine, College of Medicine and Veterinary Medicine, The University of Edinburgh
- Program Director, Diagnostic Development, OICR
- Honorary Professor, College of Medicine and Veterinary Medicine, University of Edinburgh
- Provincial Principal Investigator, Ontario Tumour Bank
- Professor (Adjunct academic staff), Department of Pathology and Molecular Medicine, Queen’s University
- Professor (Status-Only), Department of Laboratory Medicine and Pathobiology, University of Toronto
- Bartlett JMS, Sgroi DC, Treuner K, …, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019;30(11):1776-1783.
- Bayani J, Kornaga EN, Crozier C, …, Bartlett JMS. Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy–Resistant Early Breast Cancers. JCO Precis Oncol. 2019;3:1-13.
- Patel PG, Wessel T, Kawashima A, …, Bartlett JMS, Berman DM. A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancer. The Prostate. 2019;79(14):1705-1714.
- Baker AEG, Bahlmann LC, Tam RY, …, Bartlett JMS, …, Shoichet MS. Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture. Adv Mater Weinheim. 2019;31(36):e1901166.
- Sjödahl G, Jackson CL, Bartlett JM, …, Berman DM. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol. 2019;247(5):563-573.
- Bayani J, Yao CQ, Auintayo MA, …, Bartlett JMS. Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. NPJ Breast Cancer. 2017;3:3.
- Bartlett JMS, Parelukar W. Breast cancers are rare diseases-and must be treated as such. NPJ Breast Cancer. 2017;3:11.
- Kalatskaya I, Trinh QM, Spears M, …, Bartlett JMS, Stein L. ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Med. 2017;9(1):59.
- Bartlett JMS, Ahmed I, Regan MM, et al. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer. 2017;79:129-138.
- Cameron D, Morden JP, Canney P, …, Bartlett JMS, …, TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017;18(7):929-945.
- Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405-417.
- Malone ER, Saleh RR, Yu C, …, Bartlett JMS, …, Bedard PL. OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Curr Oncol. 2019;26(5):e618-e623.
- Leung SCY, Nielsen TO, Zabaglo LA, …, Bartlett JMS, …, Dowsett M. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019;75(2):225-235.
- Rimm DL, Leung SCY, Mcshane LM, …, Bartlett JMS, … Dowsett M. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod Pathol. 2019;32(1):59-69.
- Dodson A, Parry S, Ibrahim M, Bartlett JMS, …, Miller K. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. J Pathol Clin Res. 2018;4(4):262-273.
- Lee M, Tayyari F, Pinnaduwage D, …, Bartlett JMS, … Andrulis IL. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. BMC Cancer. 2018;18(1):750.
- Golan T, Stossel C, Atias D, …, Bartlett JMS, … Berger R. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer. 2018;143(1):179-183.
- Le Page C, Rahimi K, Köbel M, …, Bartlett JMS, …, Mes-Masson A-M. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer. 2018;18(1):347.
- Wolff AC, Hammond MEH, Allison KH, …, Bartlett JMS, …, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-2122.
- Brown ER, Bartlett J, Chalulu K, et al. Development of multi-disciplinary breast cancer care in Southern Malawi. Eur J Cancer Care (Engl). 2017;26(1).
Collaboration is the key to solving the big questions faced by researchers across the cancer spectrum. In Bartlett’s program there are opportunities to collaborate through technology access, partnership and mentorship. Bartlett’s expertise in diagnostic development and both in situ and deep molecular analysis of clinical specimens provides an ideal platform for partnership with researchers across Ontario, Canada and beyond. Bartlett is always willing to discuss scientific opportunities and solutions (over a coffee!) and to foster a collaborative approach with research and industry partners.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.